Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
A July meeting with the FDA could determine whether Agenus’s bot-bal combo has a shot at a 2024 filing.
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
The conference’s abstract drop features ASC4First in its plenary session.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
The company scraps its lead project and clears out its C-suite, but there was already a precedent.